General Adults Archives - Page 4 of 5

The document presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy. Priorities are for a vaccine to be administered to adolescents and adults for prevention of pulmonary tuberculosis and reduction of transmission, and for a pediatric vaccine with improved safety and efficacy as compared to BCG.

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

BCG revaccination, Hypothetical vaccines

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique

2022-2024

Ongoing

This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.

Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines

2022

BCG revaccination, M72/AS01e

Our study provides crucial information for implementing novel TB vaccines in specific target groups and on country specific acceptability and feasibility. Key groups for vaccine implementation in these settings were identified, and should be included in clinical trials and implementation planning.

Country and target population prioritization

2023-2024

BCG revaccination, Hypothetical vaccines, M72/AS01e

Ongoing

Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

2024

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.

Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa

BCG revaccination, M72/AS01e